Cite
HARVARD Citation
Denisov, L. et al. (n.d.). SAT0267 Efficacy and safety of bcd-055, proposed infliximab biosimilar, compared to infliximab: 54-week results from asart-2 phase 3 clinical study. Annals of the rheumatic diseases. p. 997. [Online].